Some astonishing results were released by Eli Lilly today on the study of Tirzepatide (the active poly-peptide in Mounjaro) in those with obesity. The results were as follows, or you can check out the video for the info as well!
The SURMOUNT-3 study looked at the effectiveness and safety of a drug called tirzepatide compared to a placebo (a dummy pill) over a 72-week period. Before the main study, participants went through a 12-week program involving a low-calorie diet, exercise, and counseling to help them lose weight.
Here are the key findings:
- At the end of the 12-week lead-in period, participants lost an average of 6.9% of their body weight.
- During the 72-week treatment period, tirzepatide was more effective than the placebo in two important ways:
1. People taking tirzepatide lost, on average, an additional 21.1% of their body weight compared to the placebo group.
2. 94.4% of those taking tirzepatide achieved an additional weight reduction of at least 5% from the starting point, while only 10.7% in the placebo group achieved the same.
In a secondary analysis:
- Participants who took tirzepatide lost an average of 26.6% of their body weight from the start of the study, after going through the 12-week lifestyle intervention and then taking tirzepatide for 72 weeks.
The full results of the study will be presented at a conference in October and later published in a scientific journal for other experts to review.
The SURMOUNT-4 study tested a drug called tirzepatide compared to a fake pill (placebo) for 52 weeks. Before that, all participants took tirzepatide for 36 weeks in an open-label period. The study had two parts: first, an open-label period where everyone took tirzepatide, and then a double-blind period where some continued on tirzepatide, while others switched to placebo.
Here are the key findings:
- During the open-label period of 36 weeks, participants lost an average of 21.1% of their body weight while on tirzepatide.
- In the double-blind period, tirzepatide was better than the placebo in helping people maintain weight loss.
- Those on tirzepatide, on average, lost an additional 6.7% of their body weight compared to those on placebo, who regained 14.8% of their weight at 88 weeks.
- Participants who stayed on tirzepatide throughout the study had a total average weight loss of 26.0% over the 88 weeks.
The full results of the study will be presented at a diabetes conference in October and later published in a scientific journal for experts to review.
Comments